Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02029040
Other study ID # STU 012013-040
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2013
Est. completion date December 2014

Study information

Verified date January 2019
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, controlled trial in the Pediatric Emergency Department. The primary objective is to determine whether nebulized 3% hypertonic saline is more effective than nebulized 0.9% saline in the treatment of bronchiolitis in the emergency department.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender All
Age group 2 Months to 12 Months
Eligibility Inclusion Criteria:

- Children 2-12 months of age presenting to Emergency Department

- Patients with a diagnosis of bronchiolitis defined as the first episode of wheezing and/or crackles in a child younger than 12 months who has physical findings of a viral respiratory infection and has no other explanation for the wheezing and/or crackles

- Patients with an RDAI score = 6 as measured by a trained respiratory therapist

Exclusion Criteria:

- Previous history of wheezing

- Known heart or lung disease

- Premature birth defined as birth before 37 weeks gestation

- Immunosuppression or immunodeficiency

- Treatment with corticosteroids in the previous 48 hours

- Critically ill children - progressive respiratory failure requiring higher level of care, vital signs instability/need for emergency interventions to prevent clinical deterioration

- Oxygen saturation <85% on room air at the time of recruitment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
3% Hypertonic Saline
Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
0.9 % normal saline
Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.

Locations

Country Name City State
United States UT Southwestern Medical Center; Children's Medical Center Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Respiratory Assessment Change Score (RACS) The primary outcome variable is the Respiratory Assessment Change Score (RACS) which is a sum of the change in the Respiratory Distress Assessment Instrument (RDAI)score plus a standardized score for the change in respiratory rate; the change in respiratory rate is assigned 1 point per each 10% change in the respiratory rate.The RDAI score is the sum of the row scores, with total range 0 to 17; higher scores indicate more severe disease. 5-15 minutes
Secondary Rate of Hospitalizations 24 hours
See also
  Status Clinical Trial Phase
Completed NCT01469845 - The SABRE Trial of Hypertonic Saline in Acute Bronchiolitis Phase 3
Completed NCT02962505 - Continuous Regional Analysis Device for Neonate Lung
Recruiting NCT02984046 - Acute Bronchiolitis and Severity Markers: Interest in Protein CC16 N/A
Completed NCT01875757 - Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life Phase 3
Completed NCT01871857 - 7% Hypertonic Saline for Acute Bronchiolitis Phase 4
Completed NCT06139029 - Comparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis Early Phase 1
Not yet recruiting NCT03915197 - Acute Bronchiolitis in Infants and Allergic Asthma N/A
Completed NCT03171142 - Effect of Heliox on RSV Bronchiolitis Phase 3
Completed NCT04245202 - Comparison of High Flow Nasal Cannula and Standard Face Mask Oxygen Therapy in Children With Bronchiolitis N/A
Not yet recruiting NCT06441162 - Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis Phase 4
Recruiting NCT02093715 - FeNO and Cytokines in Respiratory Syncytial Virus (RSV) and Non RSV Bronchiolitis in Relation to Future Asthma N/A
Not yet recruiting NCT03880903 - Hypertonic Saline Inhalation in Acute Bronchiolitis Phase 4
Completed NCT04748159 - Effects of Prone Positioning on Vital Parameters in Infants With Acute Bronchiolitis N/A
Active, not recruiting NCT04613180 - Evaluation of the Effectiveness of Montelukast in Children With Recurrent Obstructive Bronchitis Phase 4
Recruiting NCT06321133 - High Flow Nasal Cannula Weaning in Acute Bronchiolitis N/A
Recruiting NCT03753802 - Evaluation of the Effects of Respiratory Physiotherapy in Infants With Moderate Acute Bronchiolitis N/A
Withdrawn NCT01660867 - Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in the Emergency Department Phase 4